DURECT Corporation announced that the last patient has completed the study protocol in the Company's AHFIRM trial. AHFIRM is a Phase 2b randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of lasucosterol in subjects with severe alcohol-associated hepatitis (AH). A total of 301 patients were randomized and dosed in AHFIRM and DURECT plans to report topline data in the fourth quarter of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | +10.78% | +14.14% | +91.53% |
03-27 | Transcript : DURECT Corporation, Q4 2023 Earnings Call, Mar 27, 2024 | |
03-27 | DURECT Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+91.53% | 35.07M | |
+2.97% | 108B | |
+10.21% | 104B | |
+2.88% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-37.64% | 17.74B | |
-6.50% | 17.64B | |
+6.00% | 14.05B | |
+37.20% | 12.51B |
- Stock Market
- Equities
- DRRX Stock
- News DURECT Corporation
- Durect Corporation Announces Last Patient Last Visit in Phase 2B Ahfirm Trial of Larsucosterol in Alcohol-Associated Hepatitis